▶ 調査レポート

慢性腎臓病用治療薬の世界市場見通し2023年-2029年

• 英文タイトル:Drugs to Treat Chronic Kidney Disease Market, Global Outlook and Forecast 2023-2029

Market Monitor Globalが調査・発行した産業分析レポートです。慢性腎臓病用治療薬の世界市場見通し2023年-2029年 / Drugs to Treat Chronic Kidney Disease Market, Global Outlook and Forecast 2023-2029 / MRC2312MG08519資料のイメージです。• レポートコード:MRC2312MG08519
• 出版社/出版日:Market Monitor Global / 2023年12月
• レポート形態:英文、PDF、103ページ
• 納品方法:Eメール(納期:3営業日)
• 産業分類:医薬品
• 販売価格(消費税別)
  Single User¥487,500 (USD3,250)▷ お問い合わせ
  Enterprise User¥731,250 (USD4,875)▷ お問い合わせ
• ご注文方法:お問い合わせフォーム記入又はEメールでご連絡ください。
• お支払方法:銀行振込(納品後、ご請求書送付)
レポート概要
当調査レポートは次の情報を含め、世界の慢性腎臓病用治療薬市場規模と予測を収録しています。・世界の慢性腎臓病用治療薬市場:売上、2018年-2023年、2024年-2029年
・世界の慢性腎臓病用治療薬市場:販売量、2018年-2023年、2024年-2029年
・世界のトップ5企業、2022年

世界の慢性腎臓病用治療薬市場は2022年に000Mドルと評価され、予測期間中に000%のCAGRで2029年までに000Mドルに達すると予測されています。米国市場は2022年に000Mドルと推定されており、中国は2029年までに000Mドルに達すると予測されています。「カルシウム模倣薬」セグメントは今後6年間、000%のCAGRで2029年までに000Mドルに成長すると予測されています。

慢性腎臓病用治療薬のグローバル主要企業は、Pfizer Inc.、 Johnson & Johnson、 AbbVie Inc.、 Bayer AG、 Novartis AG、 Sanofi SA、 Bristol-Myers Squibb Company、 AstraZeneca plc、 Eli Lilly and Company、 C.H. Boehringer Sohn AG & Co. KG、 Amgen Inc.、 Novo Nordisk A/S、 Teva Pharmaceutical Industries Ltd.、 Otsuka Pharmaceutical Co. Ltd.、 Takeda Pharmaceutical Company Limitedなどです。2022年にトップ5企業がグローバル売上シェアの約000%を占めています。

MARKET MONITOR GLOBAL(MMG)は、慢性腎臓病用治療薬のメーカー、サプライヤー、流通業者、および業界の専門家を調査しました。これには、販売量、売上、需要、価格変動、製品タイプ、最近の動向と計画、産業トレンド、成長要因、課題、阻害要因、潜在的なリスクなどが含まれます。

【セグメント別市場分析】

世界の慢性腎臓病用治療薬市場:タイプ別、2018年-2023年、2024年-2029年
世界の慢性腎臓病用治療薬市場:タイプ別市場シェア、2022年
・カルシウム模倣薬、ビタミンD、ステロール、カリウム結合剤、カルシウム系リン酸塩結合剤

世界の慢性腎臓病用治療薬市場:用途別、2018年-2023年、2024年-2029年
世界の慢性腎臓病用治療薬市場:用途別市場シェア、2022年
・病院薬局、オンライン薬局、小売薬局

世界の慢性腎臓病用治療薬市場:地域・国別、2018年-2023年、2024年-2029年
世界の慢性腎臓病用治療薬市場:地域別市場シェア、2022年
・北米:アメリカ、カナダ、メキシコ
・ヨーロッパ:ドイツ、フランス、イギリス、イタリア、ロシア
・アジア:中国、日本、韓国、東南アジア、インド
・南米:ブラジル、アルゼンチン
・中東・アフリカ:トルコ、イスラエル、サウジアラビア、UAE

【競合分析】

また、当レポートは主要な市場参加者の分析を提供します。
・主要企業における慢性腎臓病用治療薬のグローバル売上、2018年-2023年
・主要企業における慢性腎臓病用治療薬のグローバル売上シェア、2022年
・主要企業における慢性腎臓病用治療薬のグローバル販売量、2018年-2023年
・主要企業における慢性腎臓病用治療薬のグローバル販売量シェア、2022年

さらに、当レポートは主要企業のプロファイルを提示します。
Pfizer Inc.、 Johnson & Johnson、 AbbVie Inc.、 Bayer AG、 Novartis AG、 Sanofi SA、 Bristol-Myers Squibb Company、 AstraZeneca plc、 Eli Lilly and Company、 C.H. Boehringer Sohn AG & Co. KG、 Amgen Inc.、 Novo Nordisk A/S、 Teva Pharmaceutical Industries Ltd.、 Otsuka Pharmaceutical Co. Ltd.、 Takeda Pharmaceutical Company Limited

*************************************************************

・調査・分析レポートの概要
慢性腎臓病用治療薬市場の定義
市場セグメント
世界の慢性腎臓病用治療薬市場概要
当レポートの特徴・ベネフィット
調査手法と情報源

・世界の慢性腎臓病用治療薬市場規模
世界の慢性腎臓病用治療薬市場規模:2022年 VS 2029年
世界の慢性腎臓病用治療薬市場規模と予測 2018年-2029年

・競争状況
グローバルトップ企業
売上ベースでのグローバルトップ企業
企業別グローバルでの慢性腎臓病用治療薬の売上
グローバルトップ3およびトップ5企業、2022年売上ベース
グローバル企業の慢性腎臓病用治療薬製品タイプ
グローバルにおけるティア1、ティア2、ティア3企業

・タイプ別市場分析
タイプ区分:カルシウム模倣薬、ビタミンD、ステロール、カリウム結合剤、カルシウム系リン酸塩結合剤
慢性腎臓病用治療薬のタイプ別グローバル売上・予測

・用途別市場分析
用途区分:病院薬局、オンライン薬局、小売薬局
慢性腎臓病用治療薬の用途別グローバル売上・予測

・地域別市場分析
地域別慢性腎臓病用治療薬市場規模 2022年と2029年
地域別慢性腎臓病用治療薬売上・予測
北米市場:アメリカ、カナダ、メキシコ
ヨーロッパ市場:ドイツ、フランス、イギリス、イタリア、ロシア
アジア市場:中国、日本、韓国、東南アジア、インド
南米市場:ブラジル、アルゼンチン
中東・アフリカ市場:トルコ、イスラエル、サウジアラビア、UAE

・主要企業のプロファイル(企業概要、事業概要、主要製品、売上、ニュースなど)
Pfizer Inc.、 Johnson & Johnson、 AbbVie Inc.、 Bayer AG、 Novartis AG、 Sanofi SA、 Bristol-Myers Squibb Company、 AstraZeneca plc、 Eli Lilly and Company、 C.H. Boehringer Sohn AG & Co. KG、 Amgen Inc.、 Novo Nordisk A/S、 Teva Pharmaceutical Industries Ltd.、 Otsuka Pharmaceutical Co. Ltd.、 Takeda Pharmaceutical Company Limited
...

This research report provides a comprehensive analysis of the Drugs to Treat Chronic Kidney Disease market, focusing on the current trends, market dynamics, and future prospects. The report explores the global Drugs to Treat Chronic Kidney Disease market, including major regions such as North America, Europe, Asia-Pacific, and emerging markets. It also examines key factors driving the growth of Drugs to Treat Chronic Kidney Disease, challenges faced by the industry, and potential opportunities for market players.
The global Drugs to Treat Chronic Kidney Disease market has witnessed rapid growth in recent years, driven by increasing environmental concerns, government incentives, and advancements in technology. The Drugs to Treat Chronic Kidney Disease market presents opportunities for various stakeholders, including Hospital Pharmacies, Online Pharmacies. Collaboration between the private sector and governments can accelerate the development of supportive policies, research and development efforts, and investment in Drugs to Treat Chronic Kidney Disease market. Additionally, the growing consumer demand present avenues for market expansion.
The global Drugs to Treat Chronic Kidney Disease market was valued at US$ million in 2022 and is projected to reach US$ million by 2029, at a CAGR of % during the forecast period.
Key Features:
The research report on the Drugs to Treat Chronic Kidney Disease market includes several key features to provide comprehensive insights and facilitate decision-making for stakeholders.
Executive Summary: The report provides overview of the key findings, market trends, and major insights of the Drugs to Treat Chronic Kidney Disease market.
Market Overview: The report provides a comprehensive overview of the Drugs to Treat Chronic Kidney Disease market, including its definition, historical development, and current market size. It covers market segmentation by Type (e.g., Calcimimetics, Vitamin D), region, and application, highlighting the key drivers, challenges, and opportunities within each segment.
Market Dynamics: The report analyses the market dynamics driving the growth and development of the Drugs to Treat Chronic Kidney Disease market. The report includes an assessment of government policies and regulations, technological advancements, consumer trends and preferences, infrastructure development, and industry collaborations. This analysis helps stakeholders understand the factors influencing the Drugs to Treat Chronic Kidney Disease market’s trajectory.
Competitive Landscape: The report provides an in-depth analysis of the competitive landscape within the Drugs to Treat Chronic Kidney Disease market. It includes profiles of major market players, their market share, strategies, product portfolios, and recent developments.
Market Segmentation and Forecast: The report segment the Drugs to Treat Chronic Kidney Disease market based on various parameters, such as by Type, region, and by Application. It provides market size and growth forecasts for each segment, supported by quantitative data and analysis. This helps stakeholders identify growth opportunities and make informed investment decisions.
Technological Trends: The report should highlight the key technological trends shaping the Drugs to Treat Chronic Kidney Disease market, such as advancements in Type One technology and emerging substitutes. It analyses the impact of these trends on market growth, adoption rates, and consumer preferences.
Market Challenges and Opportunities: The report identify and analyses the major challenges faced by the Drugs to Treat Chronic Kidney Disease market, such as technical bottleneck, cost limitations, and high entry barrier. It also highlights the opportunities for market growth, such as government incentives, emerging markets, and collaborations between stakeholders.
Regulatory and Policy Analysis: The report should assess the regulatory and policy landscape for Drugs to Treat Chronic Kidney Disease, including government incentives, emission standards, and infrastructure development plans. It should analyse the impact of these policies on market growth and provide insights into future regulatory developments.
Recommendations and Conclusion: The report conclude with actionable recommendations for stakeholders, such as Application One Consumer, policymakers, investors, and infrastructure providers. These recommendations should be based on the research findings and address key challenges and opportunities within the Drugs to Treat Chronic Kidney Disease market.
Supporting Data and Appendices: The report include supporting data, charts, and graphs to substantiate the analysis and findings. It also includes appendices with additional detailed information, such as data sources, survey questionnaires, and detailed market forecasts.
Market Segmentation
Drugs to Treat Chronic Kidney Disease market is split by Type and by Application. For the period 2018-2029, the growth among segments provides accurate calculations and forecasts for consumption value by Type, and by Application in terms of value.
Market segment by Type
Calcimimetics
Vitamin D
Sterols
Potassium Binders
Calcium-Based Phosphate Binders
Market segment by Application
Hospital Pharmacies
Online Pharmacies
Retail Pharmacies
Global Drugs to Treat Chronic Kidney Disease Market Segment Percentages, By Region and Country, 2022 (%)
North America
US
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Russia
Nordic Countries
Benelux
Rest of Europe
Asia
China
Japan
South Korea
Southeast Asia
India
Rest of Asia
South America
Brazil
Argentina
Rest of South America
Middle East & Africa
Turkey
Israel
Saudi Arabia
UAE
Rest of Middle East & Africa
Major players covered
Pfizer Inc.
Johnson & Johnson
AbbVie Inc.
Bayer AG
Novartis AG
Sanofi SA
Bristol-Myers Squibb Company
AstraZeneca plc
Eli Lilly and Company
C.H. Boehringer Sohn AG & Co. KG
Amgen Inc.
Novo Nordisk A/S
Teva Pharmaceutical Industries Ltd.
Otsuka Pharmaceutical Co. Ltd.
Takeda Pharmaceutical Company Limited
Outline of Major Chapters:
Chapter 1: Introduces the definition of Drugs to Treat Chronic Kidney Disease, market overview.
Chapter 2: Global Drugs to Treat Chronic Kidney Disease market size in revenue.
Chapter 3: Detailed analysis of Drugs to Treat Chronic Kidney Disease company competitive landscape, revenue and market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Sales of Drugs to Treat Chronic Kidney Disease in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space of each country in the world.
Chapter 7: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 8: The main points and conclusions of the report.

レポート目次

1 Introduction to Research & Analysis Reports
1.1 Drugs to Treat Chronic Kidney Disease Market Definition
1.2 Market Segments
1.2.1 Market by Type
1.2.2 Market by Application
1.3 Global Drugs to Treat Chronic Kidney Disease Market Overview
1.4 Features & Benefits of This Report
1.5 Methodology & Sources of Information
1.5.1 Research Methodology
1.5.2 Research Process
1.5.3 Base Year
1.5.4 Report Assumptions & Caveats
2 Global Drugs to Treat Chronic Kidney Disease Overall Market Size
2.1 Global Drugs to Treat Chronic Kidney Disease Market Size: 2022 VS 2029
2.2 Global Drugs to Treat Chronic Kidney Disease Market Size, Prospects & Forecasts: 2018-2029
2.3 Key Market Trends, Opportunity, Drivers and Restraints
2.3.1 Market Opportunities & Trends
2.3.2 Market Drivers
2.3.3 Market Restraints
3 Company Landscape
3.1 Top Drugs to Treat Chronic Kidney Disease Players in Global Market
3.2 Top Global Drugs to Treat Chronic Kidney Disease Companies Ranked by Revenue
3.3 Global Drugs to Treat Chronic Kidney Disease Revenue by Companies
3.4 Top 3 and Top 5 Drugs to Treat Chronic Kidney Disease Companies in Global Market, by Revenue in 2022
3.5 Global Companies Drugs to Treat Chronic Kidney Disease Product Type
3.6 Tier 1, Tier 2 and Tier 3 Drugs to Treat Chronic Kidney Disease Players in Global Market
3.6.1 List of Global Tier 1 Drugs to Treat Chronic Kidney Disease Companies
3.6.2 List of Global Tier 2 and Tier 3 Drugs to Treat Chronic Kidney Disease Companies
4 Market Sights by Product
4.1 Overview
4.1.1 By Type – Global Drugs to Treat Chronic Kidney Disease Market Size Markets, 2022 & 2029
4.1.2 Calcimimetics
4.1.3 Vitamin D
4.1.4 Sterols
4.1.5 Potassium Binders
4.1.6 Calcium-Based Phosphate Binders
4.2 By Type – Global Drugs to Treat Chronic Kidney Disease Revenue & Forecasts
4.2.1 By Type – Global Drugs to Treat Chronic Kidney Disease Revenue, 2018-2023
4.2.2 By Type – Global Drugs to Treat Chronic Kidney Disease Revenue, 2024-2029
4.2.3 By Type – Global Drugs to Treat Chronic Kidney Disease Revenue Market Share, 2018-2029
5 Sights by Application
5.1 Overview
5.1.1 By Application – Global Drugs to Treat Chronic Kidney Disease Market Size, 2022 & 2029
5.1.2 Hospital Pharmacies
5.1.3 Online Pharmacies
5.1.4 Retail Pharmacies
5.2 By Application – Global Drugs to Treat Chronic Kidney Disease Revenue & Forecasts
5.2.1 By Application – Global Drugs to Treat Chronic Kidney Disease Revenue, 2018-2023
5.2.2 By Application – Global Drugs to Treat Chronic Kidney Disease Revenue, 2024-2029
5.2.3 By Application – Global Drugs to Treat Chronic Kidney Disease Revenue Market Share, 2018-2029
6 Sights by Region
6.1 By Region – Global Drugs to Treat Chronic Kidney Disease Market Size, 2022 & 2029
6.2 By Region – Global Drugs to Treat Chronic Kidney Disease Revenue & Forecasts
6.2.1 By Region – Global Drugs to Treat Chronic Kidney Disease Revenue, 2018-2023
6.2.2 By Region – Global Drugs to Treat Chronic Kidney Disease Revenue, 2024-2029
6.2.3 By Region – Global Drugs to Treat Chronic Kidney Disease Revenue Market Share, 2018-2029
6.3 North America
6.3.1 By Country – North America Drugs to Treat Chronic Kidney Disease Revenue, 2018-2029
6.3.2 US Drugs to Treat Chronic Kidney Disease Market Size, 2018-2029
6.3.3 Canada Drugs to Treat Chronic Kidney Disease Market Size, 2018-2029
6.3.4 Mexico Drugs to Treat Chronic Kidney Disease Market Size, 2018-2029
6.4 Europe
6.4.1 By Country – Europe Drugs to Treat Chronic Kidney Disease Revenue, 2018-2029
6.4.2 Germany Drugs to Treat Chronic Kidney Disease Market Size, 2018-2029
6.4.3 France Drugs to Treat Chronic Kidney Disease Market Size, 2018-2029
6.4.4 U.K. Drugs to Treat Chronic Kidney Disease Market Size, 2018-2029
6.4.5 Italy Drugs to Treat Chronic Kidney Disease Market Size, 2018-2029
6.4.6 Russia Drugs to Treat Chronic Kidney Disease Market Size, 2018-2029
6.4.7 Nordic Countries Drugs to Treat Chronic Kidney Disease Market Size, 2018-2029
6.4.8 Benelux Drugs to Treat Chronic Kidney Disease Market Size, 2018-2029
6.5 Asia
6.5.1 By Region – Asia Drugs to Treat Chronic Kidney Disease Revenue, 2018-2029
6.5.2 China Drugs to Treat Chronic Kidney Disease Market Size, 2018-2029
6.5.3 Japan Drugs to Treat Chronic Kidney Disease Market Size, 2018-2029
6.5.4 South Korea Drugs to Treat Chronic Kidney Disease Market Size, 2018-2029
6.5.5 Southeast Asia Drugs to Treat Chronic Kidney Disease Market Size, 2018-2029
6.5.6 India Drugs to Treat Chronic Kidney Disease Market Size, 2018-2029
6.6 South America
6.6.1 By Country – South America Drugs to Treat Chronic Kidney Disease Revenue, 2018-2029
6.6.2 Brazil Drugs to Treat Chronic Kidney Disease Market Size, 2018-2029
6.6.3 Argentina Drugs to Treat Chronic Kidney Disease Market Size, 2018-2029
6.7 Middle East & Africa
6.7.1 By Country – Middle East & Africa Drugs to Treat Chronic Kidney Disease Revenue, 2018-2029
6.7.2 Turkey Drugs to Treat Chronic Kidney Disease Market Size, 2018-2029
6.7.3 Israel Drugs to Treat Chronic Kidney Disease Market Size, 2018-2029
6.7.4 Saudi Arabia Drugs to Treat Chronic Kidney Disease Market Size, 2018-2029
6.7.5 UAE Drugs to Treat Chronic Kidney Disease Market Size, 2018-2029
7 Drugs to Treat Chronic Kidney Disease Companies Profiles
7.1 Pfizer Inc.
7.1.1 Pfizer Inc. Company Summary
7.1.2 Pfizer Inc. Business Overview
7.1.3 Pfizer Inc. Drugs to Treat Chronic Kidney Disease Major Product Offerings
7.1.4 Pfizer Inc. Drugs to Treat Chronic Kidney Disease Revenue in Global Market (2018-2023)
7.1.5 Pfizer Inc. Key News & Latest Developments
7.2 Johnson & Johnson
7.2.1 Johnson & Johnson Company Summary
7.2.2 Johnson & Johnson Business Overview
7.2.3 Johnson & Johnson Drugs to Treat Chronic Kidney Disease Major Product Offerings
7.2.4 Johnson & Johnson Drugs to Treat Chronic Kidney Disease Revenue in Global Market (2018-2023)
7.2.5 Johnson & Johnson Key News & Latest Developments
7.3 AbbVie Inc.
7.3.1 AbbVie Inc. Company Summary
7.3.2 AbbVie Inc. Business Overview
7.3.3 AbbVie Inc. Drugs to Treat Chronic Kidney Disease Major Product Offerings
7.3.4 AbbVie Inc. Drugs to Treat Chronic Kidney Disease Revenue in Global Market (2018-2023)
7.3.5 AbbVie Inc. Key News & Latest Developments
7.4 Bayer AG
7.4.1 Bayer AG Company Summary
7.4.2 Bayer AG Business Overview
7.4.3 Bayer AG Drugs to Treat Chronic Kidney Disease Major Product Offerings
7.4.4 Bayer AG Drugs to Treat Chronic Kidney Disease Revenue in Global Market (2018-2023)
7.4.5 Bayer AG Key News & Latest Developments
7.5 Novartis AG
7.5.1 Novartis AG Company Summary
7.5.2 Novartis AG Business Overview
7.5.3 Novartis AG Drugs to Treat Chronic Kidney Disease Major Product Offerings
7.5.4 Novartis AG Drugs to Treat Chronic Kidney Disease Revenue in Global Market (2018-2023)
7.5.5 Novartis AG Key News & Latest Developments
7.6 Sanofi SA
7.6.1 Sanofi SA Company Summary
7.6.2 Sanofi SA Business Overview
7.6.3 Sanofi SA Drugs to Treat Chronic Kidney Disease Major Product Offerings
7.6.4 Sanofi SA Drugs to Treat Chronic Kidney Disease Revenue in Global Market (2018-2023)
7.6.5 Sanofi SA Key News & Latest Developments
7.7 Bristol-Myers Squibb Company
7.7.1 Bristol-Myers Squibb Company Company Summary
7.7.2 Bristol-Myers Squibb Company Business Overview
7.7.3 Bristol-Myers Squibb Company Drugs to Treat Chronic Kidney Disease Major Product Offerings
7.7.4 Bristol-Myers Squibb Company Drugs to Treat Chronic Kidney Disease Revenue in Global Market (2018-2023)
7.7.5 Bristol-Myers Squibb Company Key News & Latest Developments
7.8 AstraZeneca plc
7.8.1 AstraZeneca plc Company Summary
7.8.2 AstraZeneca plc Business Overview
7.8.3 AstraZeneca plc Drugs to Treat Chronic Kidney Disease Major Product Offerings
7.8.4 AstraZeneca plc Drugs to Treat Chronic Kidney Disease Revenue in Global Market (2018-2023)
7.8.5 AstraZeneca plc Key News & Latest Developments
7.9 Eli Lilly and Company
7.9.1 Eli Lilly and Company Company Summary
7.9.2 Eli Lilly and Company Business Overview
7.9.3 Eli Lilly and Company Drugs to Treat Chronic Kidney Disease Major Product Offerings
7.9.4 Eli Lilly and Company Drugs to Treat Chronic Kidney Disease Revenue in Global Market (2018-2023)
7.9.5 Eli Lilly and Company Key News & Latest Developments
7.10 C.H. Boehringer Sohn AG & Co. KG
7.10.1 C.H. Boehringer Sohn AG & Co. KG Company Summary
7.10.2 C.H. Boehringer Sohn AG & Co. KG Business Overview
7.10.3 C.H. Boehringer Sohn AG & Co. KG Drugs to Treat Chronic Kidney Disease Major Product Offerings
7.10.4 C.H. Boehringer Sohn AG & Co. KG Drugs to Treat Chronic Kidney Disease Revenue in Global Market (2018-2023)
7.10.5 C.H. Boehringer Sohn AG & Co. KG Key News & Latest Developments
7.11 Amgen Inc.
7.11.1 Amgen Inc. Company Summary
7.11.2 Amgen Inc. Business Overview
7.11.3 Amgen Inc. Drugs to Treat Chronic Kidney Disease Major Product Offerings
7.11.4 Amgen Inc. Drugs to Treat Chronic Kidney Disease Revenue in Global Market (2018-2023)
7.11.5 Amgen Inc. Key News & Latest Developments
7.12 Novo Nordisk A/S
7.12.1 Novo Nordisk A/S Company Summary
7.12.2 Novo Nordisk A/S Business Overview
7.12.3 Novo Nordisk A/S Drugs to Treat Chronic Kidney Disease Major Product Offerings
7.12.4 Novo Nordisk A/S Drugs to Treat Chronic Kidney Disease Revenue in Global Market (2018-2023)
7.12.5 Novo Nordisk A/S Key News & Latest Developments
7.13 Teva Pharmaceutical Industries Ltd.
7.13.1 Teva Pharmaceutical Industries Ltd. Company Summary
7.13.2 Teva Pharmaceutical Industries Ltd. Business Overview
7.13.3 Teva Pharmaceutical Industries Ltd. Drugs to Treat Chronic Kidney Disease Major Product Offerings
7.13.4 Teva Pharmaceutical Industries Ltd. Drugs to Treat Chronic Kidney Disease Revenue in Global Market (2018-2023)
7.13.5 Teva Pharmaceutical Industries Ltd. Key News & Latest Developments
7.14 Otsuka Pharmaceutical Co. Ltd.
7.14.1 Otsuka Pharmaceutical Co. Ltd. Company Summary
7.14.2 Otsuka Pharmaceutical Co. Ltd. Business Overview
7.14.3 Otsuka Pharmaceutical Co. Ltd. Drugs to Treat Chronic Kidney Disease Major Product Offerings
7.14.4 Otsuka Pharmaceutical Co. Ltd. Drugs to Treat Chronic Kidney Disease Revenue in Global Market (2018-2023)
7.14.5 Otsuka Pharmaceutical Co. Ltd. Key News & Latest Developments
7.15 Takeda Pharmaceutical Company Limited
7.15.1 Takeda Pharmaceutical Company Limited Company Summary
7.15.2 Takeda Pharmaceutical Company Limited Business Overview
7.15.3 Takeda Pharmaceutical Company Limited Drugs to Treat Chronic Kidney Disease Major Product Offerings
7.15.4 Takeda Pharmaceutical Company Limited Drugs to Treat Chronic Kidney Disease Revenue in Global Market (2018-2023)
7.15.5 Takeda Pharmaceutical Company Limited Key News & Latest Developments
8 Conclusion
9 Appendix
9.1 Note
9.2 Examples of Clients
9.3 Disclaimer